{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/48301"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/48301","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Investigating the impact of IL-17A signaling in osteoclasts and osteoblasts on bone loss in spondyloarthritis and estrogen deficiency","abstract":"INTRODUCTION: Diverging bone phenotypes have been described in spondylarthritis. Both pathogenic new bone formation and bone loss are observed which may be explained by pleiotropic effects of IL-17A. Studies in mice have yielded contradictory results regarding the effect of IL-17A signaling in osteoclasts and osteoblasts. As IL-17A signals through a receptor composed of IL-17RA and IL-17RC chains, we sought to elucidate the bone phenotypes caused by IL-17A-mediated inflammation in mice with cell-type specific conditional deletion of the Il17rc gene. METHODS: Il17rcf/f mice were crossed with Cathepsin K-cre (Ctsk-cre) and Prx1-cre driver mice to abrogate IL-17A signaling in osteoclasts and mesenchymal cells, respectively. Baseline studies were conducted in 12-week-old male and female Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice. A second cohort of female mice underwent ovariectomy (OVX) or sham surgery at 12 weeks of age with analysis 8 weeks post OVX. A third cohort of male mice was hydrodynamically injected with IL-23 minicircles at 8 weeks of age. Animals were weighed weekly and analyzed after 4 weeks. For each cohort, cortical and trabecular bone parameters were measured by micro-CT. Serum was harvested for analysis of CTX-1, P1NP and IL-17A by ELISA. In a separate experiment, osteoclast precursors in the bone marrow were quantified by flow cytometry 2 weeks after OVX. RESULTS: There were no baseline differences in trabecular or cortical bone parameters, CTX-1, P1NP, or IL-17A serum concentrations between Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice. In contrast, OVX-induced bone loss was partially abrogated in Ctsk-cre mice (Figure 1), without significant differences in IL-17A, CTX-1 or P1NP serum concentrations between genotypes. The frequency of osteoclast precursors decreased after OVX compared with sham, without significant differences between Il17rcf/f and Il17rcf/f.Ctk-cre mice. Significant trabecular bone loss was observed in response to IL-23 minicircle injection. However, there were no significant differences in bone parameters between Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice overexpressing IL-23. CONCLUSIONS: Mice with conditional deletion of Il17rc in osteoclasts or mesenchymal cells, respectively, had phenotypically normal bones at baseline. Il17rc deletion in osteoclasts (Ctsk-cre mice) partially abrogated the bone loss induced by OVX. In contrast, bone loss due to IL-23 overexpression appeared to be independent of IL-17A signaling in osteoclasts or osteoblasts.","abstract_html":"INTRODUCTION: Diverging bone phenotypes have been described in spondylarthritis. Both pathogenic new bone formation and bone loss are observed which may be explained by pleiotropic effects of IL-17A. Studies in mice have yielded contradictory results regarding the effect of IL-17A signaling in osteoclasts and osteoblasts. As IL-17A signals through a receptor composed of IL-17RA and IL-17RC chains, we sought to elucidate the bone phenotypes caused by IL-17A-mediated inflammation in mice with cell-type specific conditional deletion of the Il17rc gene. METHODS: Il17rcf/f mice were crossed with Cathepsin K-cre (Ctsk-cre) and Prx1-cre driver mice to abrogate IL-17A signaling in osteoclasts and mesenchymal cells, respectively. Baseline studies were conducted in 12-week-old male and female Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice. A second cohort of female mice underwent ovariectomy (OVX) or sham surgery at 12 weeks of age with analysis 8 weeks post OVX. A third cohort of male mice was hydrodynamically injected with IL-23 minicircles at 8 weeks of age. Animals were weighed weekly and analyzed after 4 weeks. For each cohort, cortical and trabecular bone parameters were measured by micro-CT. Serum was harvested for analysis of CTX-1, P1NP and IL-17A by ELISA. In a separate experiment, osteoclast precursors in the bone marrow were quantified by flow cytometry 2 weeks after OVX. RESULTS: There were no baseline differences in trabecular or cortical bone parameters, CTX-1, P1NP, or IL-17A serum concentrations between Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice. In contrast, OVX-induced bone loss was partially abrogated in Ctsk-cre mice (Figure 1), without significant differences in IL-17A, CTX-1 or P1NP serum concentrations between genotypes. The frequency of osteoclast precursors decreased after OVX compared with sham, without significant differences between Il17rcf/f and Il17rcf/f.Ctk-cre mice. Significant trabecular bone loss was observed in response to IL-23 minicircle injection. However, there were no significant differences in bone parameters between Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice overexpressing IL-23. CONCLUSIONS: Mice with conditional deletion of Il17rc in osteoclasts or mesenchymal cells, respectively, had phenotypically normal bones at baseline. Il17rc deletion in osteoclasts (Ctsk-cre mice) partially abrogated the bone loss induced by OVX. In contrast, bone loss due to IL-23 overexpression appeared to be independent of IL-17A signaling in osteoclasts or osteoblasts.","abstract_has_math":false,"creators":["Martorana, Makayla"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Ermann, Joerg","Wisco, Jonathan"],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023","date_published":"2023","updated_at":"2026-11-19T02:41:58Z","subjects":["Immunology"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/48301","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/48301","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F48301","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Ermann, Joerg","Wisco, Jonathan"]},{"key":"dc:creator","label":"Author","values":["Martorana, Makayla"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2024-03-05T17:50:17Z"]},{"key":"dc:date.embargo","label":"Dc Date Embargo","values":["2025-03-01T00:00:00Z"]},{"key":"dc:date.issued","label":"Date","values":["2023"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2024-03-01T17:04:58Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Immunology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/48301"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["INTRODUCTION: Diverging bone phenotypes have been described in spondylarthritis. Both pathogenic new bone formation and bone loss are observed which may be explained by pleiotropic effects of IL-17A. Studies in mice have yielded contradictory results regarding the effect of IL-17A signaling in osteoclasts and osteoblasts. As IL-17A signals through a receptor composed of IL-17RA and IL-17RC chains, we sought to elucidate the bone phenotypes caused by IL-17A-mediated inflammation in mice with cell-type specific conditional deletion of the Il17rc gene. METHODS: Il17rcf/f mice were crossed with Cathepsin K-cre (Ctsk-cre) and Prx1-cre driver mice to abrogate IL-17A signaling in osteoclasts and mesenchymal cells, respectively. Baseline studies were conducted in 12-week-old male and female Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice. A second cohort of female mice underwent ovariectomy (OVX) or sham surgery at 12 weeks of age with analysis 8 weeks post OVX. A third cohort of male mice was hydrodynamically injected with IL-23 minicircles at 8 weeks of age. Animals were weighed weekly and analyzed after 4 weeks. For each cohort, cortical and trabecular bone parameters were measured by micro-CT. Serum was harvested for analysis of CTX-1, P1NP and IL-17A by ELISA. In a separate experiment, osteoclast precursors in the bone marrow were quantified by flow cytometry 2 weeks after OVX. RESULTS: There were no baseline differences in trabecular or cortical bone parameters, CTX-1, P1NP, or IL-17A serum concentrations between Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice. In contrast, OVX-induced bone loss was partially abrogated in Ctsk-cre mice (Figure 1), without significant differences in IL-17A, CTX-1 or P1NP serum concentrations between genotypes. The frequency of osteoclast precursors decreased after OVX compared with sham, without significant differences between Il17rcf/f and Il17rcf/f.Ctk-cre mice. Significant trabecular bone loss was observed in response to IL-23 minicircle injection. However, there were no significant differences in bone parameters between Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice overexpressing IL-23. CONCLUSIONS: Mice with conditional deletion of Il17rc in osteoclasts or mesenchymal cells, respectively, had phenotypically normal bones at baseline. Il17rc deletion in osteoclasts (Ctsk-cre mice) partially abrogated the bone loss induced by OVX. In contrast, bone loss due to IL-23 overexpression appeared to be independent of IL-17A signaling in osteoclasts or osteoblasts."]},{"key":"dc:title","label":"Title","values":["Investigating the impact of IL-17A signaling in osteoclasts and osteoblasts on bone loss in spondyloarthritis and estrogen deficiency"]}]}],"canonical_facts":{"dc:contributor.advisor":["Ermann, Joerg","Wisco, Jonathan"],"dc:creator":["Martorana, Makayla"],"dc:date.accessioned":["2024-03-05T17:50:17Z"],"dc:date.embargo":["2025-03-01T00:00:00Z"],"dc:date.issued":["2023"],"dc:date.updated":["2024-03-01T17:04:58Z"],"dc:description.abstract":["INTRODUCTION: Diverging bone phenotypes have been described in spondylarthritis. Both pathogenic new bone formation and bone loss are observed which may be explained by pleiotropic effects of IL-17A. Studies in mice have yielded contradictory results regarding the effect of IL-17A signaling in osteoclasts and osteoblasts. As IL-17A signals through a receptor composed of IL-17RA and IL-17RC chains, we sought to elucidate the bone phenotypes caused by IL-17A-mediated inflammation in mice with cell-type specific conditional deletion of the Il17rc gene. METHODS: Il17rcf/f mice were crossed with Cathepsin K-cre (Ctsk-cre) and Prx1-cre driver mice to abrogate IL-17A signaling in osteoclasts and mesenchymal cells, respectively. Baseline studies were conducted in 12-week-old male and female Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice. A second cohort of female mice underwent ovariectomy (OVX) or sham surgery at 12 weeks of age with analysis 8 weeks post OVX. A third cohort of male mice was hydrodynamically injected with IL-23 minicircles at 8 weeks of age. Animals were weighed weekly and analyzed after 4 weeks. For each cohort, cortical and trabecular bone parameters were measured by micro-CT. Serum was harvested for analysis of CTX-1, P1NP and IL-17A by ELISA. In a separate experiment, osteoclast precursors in the bone marrow were quantified by flow cytometry 2 weeks after OVX. RESULTS: There were no baseline differences in trabecular or cortical bone parameters, CTX-1, P1NP, or IL-17A serum concentrations between Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice. In contrast, OVX-induced bone loss was partially abrogated in Ctsk-cre mice (Figure 1), without significant differences in IL-17A, CTX-1 or P1NP serum concentrations between genotypes. The frequency of osteoclast precursors decreased after OVX compared with sham, without significant differences between Il17rcf/f and Il17rcf/f.Ctk-cre mice. Significant trabecular bone loss was observed in response to IL-23 minicircle injection. However, there were no significant differences in bone parameters between Il17rcf/f, Il17rcf/f.Ctsk-cre and Il17rcf/f.Prx1-cre mice overexpressing IL-23. CONCLUSIONS: Mice with conditional deletion of Il17rc in osteoclasts or mesenchymal cells, respectively, had phenotypically normal bones at baseline. Il17rc deletion in osteoclasts (Ctsk-cre mice) partially abrogated the bone loss induced by OVX. In contrast, bone loss due to IL-23 overexpression appeared to be independent of IL-17A signaling in osteoclasts or osteoblasts."],"dc:identifier.uri":["https://hdl.handle.net/2144/48301"],"dc:language.iso":["en_US"],"dc:subject":["Immunology"],"dc:title":["Investigating the impact of IL-17A signaling in osteoclasts and osteoblasts on bone loss in spondyloarthritis and estrogen deficiency"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-19T02:41:58Z"}